Clinical Trial

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

Study acronym: RAISE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2024-01-17; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2024-08-05
Trial Details
NCT Number NCT06226805
Lead Sponsor Basking Biosciences, Inc.
Conditions Acute Ischemic Stroke
Enrollment 228 participants
Start Date 2024-07-31
Primary Completion 2027-06 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-14